Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Oral Terbinafine in Combination With Other Oral Anti-Fungal Agents for Treatment of Refractory Dermatophytosis
NCT07816510Completed
- Sponsor
- Chattogram Medical College
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Randomised, open-label trial in dermatophytosis comparing Terbinafine + Fluconazole, Terbinafine + Itraconazole and Terbinafine + Voriconazole (3 arms). Primary endpoints: Cure Rate at 6 weeks and Adverse Effects at 6 weeks. Started Mar 2021; status: completed.
02
Drugs
Terbinafinefluconazoleitraconazolevoriconazole
03
Conditions
dermatophytosis
Beyond the preview
Go deeper on NCT07816510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07816510.